title: Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy.
abstract: Transduction of malignant cells with toxin genes provides a novel strategy by which to promote tumor cell destruction. Whereas the capacity of the toxin gene/prodrug combination cytosine deaminase/fluorocytosine to inhibit growth of human metastatic pulmonary adenocarcinoma cell lines in vitro is established, the in vivo efficacy of this binary system has not yet been determined. For the development of toxin gene therapy for the treatment of lung adenocarcinoma metastatic to the pleural space, a reliable, disease-specific model is required. The serosa of the rat small intestine resembles the basal lamina of the pleura and provides the basis for a more convenient model than direct injection of tumor into the pleural space. Adenocarcinoma cells are inoculated into everted denuded rat intestine configured as a sac. Immunocytochemical and histological analyses show rapid cell growth with characteristics that mimic nodular metastatic intrapleural disease. In the context of this model, systemically delivered fluorocytosine significantly inhibits the growth of cytosine deaminase-expressing human lung adenocarcinoma cells. The dosing schedule required 30 days; neither addition of an enzyme inhibitor that increases the half-life of fluorocytosine nor intralumenal drug delivery is effective in shortening (to 15 days) the protocol. We conclude that CD continues to hold promise as a toxin gene for lung adenocarcinoma gene therapy, and that prolonged prodrug administration may be required for maximum efficacy.
authors.affiliation: Department of Medicine, University of North Carolina at Chapel Hill, 27599, USA.
authors.forename: D K
authors.initials: DK
authors.lastname: Hoganson
authors.forename: H
authors.initials: H
authors.lastname: Matsui
authors.forename: R K
authors.initials: RK
authors.lastname: Batra
authors.forename: R C
authors.initials: RC
authors.lastname: Boucher
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D043525:Cytosine Deaminase; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000235:genetics*; D005437:Flucytosine / Q000627:therapeutic use; D005798:Genes, Bacterial / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009368:Neoplasm Transplantation; D009700:Nucleoside Deaminases / Q000235:genetics; D010997:Pleural Neoplasms / Q000473:pathology / Q000628:therapy*; D011355:Prodrugs; D051381:Rats; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D011355:Prodrugs; D005437:Flucytosine; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase